[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,77,0,25,[9,47,77,104,134,162,187,213,238,266,291,315,329,351,373,393,420,443,472,504,529,557,587,609,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053348","phase-1-kisspeptin-to-quantify-gnrh-neuronal-function-in-health-and-disease-100053348",false,"NCT07224490","Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol or the interpretation of results\n* Active use of illicit drugs (not including marijuana)\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* Surgical or natural menopause","ALL","18 Years","60 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.",[27,28,29,30],"Reproductive Disorder","Neurodegeneration","SARS-CoV 2","Long COVID",[32,28,29,33,30],"Reproductive disorder","Kisspeptin","RECRUITING","2026-07-09",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2026-03-10",{"date":42,"type":21},"2030-05",{"name":44,"class":45},"Stephanie B. Seminara, MD","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100053400","fatigue-in-long-covid-100053400","NCT07697261","Fatigue in Long COVID","Fatigue in Long COVID Managed With Conservative Care: An International, Randomized Controlled Trial (FALCON Trial)","FALCON","Inclusion Criteria:\n\n* The inclusion criteria for participants are:\n\n  1. Adults aged 18 to 65 years\n  2. Meeting the WHO clinical case definition for long COVID and\n  3. Self-reported experiencing long COVID symptoms such as fatigue, muscle pain, and brain fog.\n  4. Reporting a minimum score of ≥35 on the Checklist Individual Strength CIS-fatigue domain.\n  5. Able to speak and read English\n  6. Scoring higher in contemplation, action or maintenance scores than the precontemplation phase on the readiness to change questionnaire\n  7. Provides consent for study participation.\n  8. Consistent access to an internet-connected device (e.g., smartphone, tablet, laptop) that can facilitate access to the study interventions.\n\nExclusion Criteria:\n\n* The exclusion criteria are:\n\n  1. Long COVID participants whose presentation is primarily restricted to anosmia.\n  2. Participants with Post-Intensive Care Syndrome (PICS) or serious organic sequelae of COVID-19, such as structural lung injury attributable to mechanical ventilation or other organ damage requiring ongoing specialist management.\n  3. Participants who will not be able to attend intervention sessions or follow up visits due to anticipated significant life changes or relocation.\n  4. Unable to provide informed consent (e.g. cognitive disability, language barrier)\n  5. Co-morbidities that likely to impair function for as long or longer than long COVID\n  6. Current participation in psychotherapy, structured physical rehabilitation (e.g., physiotherapy or occupational therapy), or another trial that does not permit co-enrollment.","65 Years",{"count":57,"type":21},100,[59],"NA","Long COVID affects about 6 in 100 people after a COVID-19 infection. It can cause ongoing problems like ongoing tiredness, muscle pain, and \"brain fog.\" We know very little about which treatments might be helpful for long COVID.\n\nThe goal of this trial is to compare two treatments for people with long COVID to try to manage their symptoms. The main question is to assess whether the Lightning Process is effective for people living with long COVID compared to activity pacing. Each person will be placed into one of the two groups randomly (by chance, like flipping a coin). Activity pacing helps people balance rest and daily activities. The Lightning Process teaches ways to change thought patterns and body responses to symptoms. We will include 100 adults with long COVID. Everything will be done online, including filling out surveys about health and daily life. The goal is to find out which approach helps people feel better and improve their daily activities.",[30],[63,64,65,66,67],"long COVID","Lightning Process","activity pacing","post-exertional malaise","fatigue","NOT_YET_RECRUITING","2026-07-07",{"date":37,"type":38},{"date":72,"type":21},"2026-11",{"date":74,"type":21},"2028-12",{"name":76,"class":45},"McMaster University",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100645261","phase-1-taurine-supplementation-in-adolescents-with-post-covid-condition-100645261","NCT07682402","Taurine Supplementation in Adolescents With Post-COVID Condition","An Open-Label Study of Taurine Supplementation in Adolescents With Post-COVID Condition: Quantifying Taurine Plasma Levels and Evaluating Clinical and Biological Outcomes","TaurineLCPeds","Inclusion Criteria:\n\n1. Subjects must be between 10 and 17 years of age at the time of study enrollment\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to trial; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to trial enrollment.\n3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.\n5. Lingering symptoms from COVID-19 present at the time of trial enrollment.\n6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Medication(s) only available through a prescription for the purposes of treating fatigue or cognitive function have been discontinued for four weeks prior to randomization.\n8. Participants must be able to assent to their participation in the study and be both willing and able to comply with study requirements.\n9. Parents\u002Fcaregivers\u002Fguardians must be able to provide informed consent for participation.\n10. Participants must agree to avoid taking supplemental taurine (e.g. from over-the-counter preparations, energy drinks, etc.)\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.\n2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.\n3. Contraindications to the study intervention.\n4. Currently already on the study intervention (Participants would be eligible if they stopped taking Taurine for a minimum of 4 weeks prior to enrollment).\n5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted).\n6. Currently pregnant or breastfeeding.\n7. The participant is currently enrolled in another research trial to treat neurocognitive symptoms in LC.","10 Years","17 Years",{"count":88,"type":21},30,[24,90],"PHASE2","The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19 (PASC), has emerged as a complex multisystemic condition and challenging public health issue.\n\nContrary to initial perceptions, pediatric Long COVID is a significant health concern, with studies suggesting its prevalence ranges from 10% to 25% following infection. Research in the pediatric population has largely been limited to observational studies based on self-reported symptoms or large electronic healthcare datasets. The long-term outcomes and predictors of LC in children remain poorly described, highlighting an urgent need for further mechanistic research to characterize this complex condition. While acute COVID-19 symptoms are often milder in children relative to adults, some go on to develop a range of chronic physical, immunological, psychological, and neurological symptoms persisting for weeks to years after initial infection. The most commonly reported symptoms are similar to those seen in adults and include debilitating fatigue, respiratory distress, headaches, gastrointestinal symptoms, and neurocognitive impairment. Other frequently reported symptoms include muscle pain, sleep disturbances, olfactory and gustatory disturbances, exercise intolerance, and heart palpitations\u002Fcardiovascular symptoms. These symptoms can be new, or they may persist or fluctuate from the initial illness. Additionally, many children with LC experience psychological symptoms such as anxiety, depression, and mood disturbances, which are thought to be exacerbated by experiencing prolonged illness and subsequent lifestyle disruptions.\n\nCurrently, effective treatments for LC remain elusive, leaving patients to contend with persistent symptoms that significantly impair their quality of life. For children and adolescents, these issues can profoundly impact their daily activities, academic performance, and social interactions\u002Ffriendships. Symptoms like debilitating fatigue, cognitive impairment, and mood disturbances are especially disruptive by interfering with memory, energy levels, and overall development, often leading to school absenteeism, social withdrawal, and psychological distress. Therefore, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.",[30,93,94],"Post COVID-19 Condition","PASC Post Acute Sequelae of COVID 19","2026-06-26",{"date":97,"type":38},"2026-07-02",{"date":99,"type":21},"2026-09-30",{"date":101,"type":21},"2028-12-31",{"name":103,"class":45},"University of Alberta",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100641535","perceive-outreach-a-scalable-risk-based-model-for-managing-persistent-cardiovascular-impact-in-long-covid-100641535","NCT07661862","PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID","Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID","Inclusion Criteria:\n\n* Aged forty years or older\n* Impaired estimated functional capacity using DASI as proxy (defined by age-normative metabolic equivalent of tasks \\[METs\\])\n* History of COVID-19 (stratified by hospital admission)\n* Currently symptomatic with fatigue, dyspnoea or chest pain symptoms\n* Medicare eligibility\n* Ability and willingness to provide written informed consent to participate in the study. The patient will need to be able to communicate fluently with the investigator. The investigator will need to be satisfied that the patient understands the study by having them explain the study plan back to the investigator.\n\nExclusion Criteria:\n\n* Unable to provide written informed consent to participate in this study\n* Participating in another research trial where randomized treatment would be unacceptable\n* Mobility impairment that would impact participants' ability to perform exercise\n* History of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS)\n* Known valvular stenosis or regurgitation of \\>moderate severity, history of previous heart failure (baseline New York Heart Association \\[NYHA\\] \\>2)\n* Oncologic (or other) life expectancy \\\u003C12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial","40 Years",{"count":113,"type":21},577,[59],"Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called \"Long COVID\" or Post-Acute Sequelae of SARS-CoV-2 (PASC). For some people, Long COVID can affect the heart and lungs, making it harder to exercise or carry out daily activities. It can also affect mental health and quality of life.\n\nThis study is testing a new care model called PERCEIVE-Outreach, designed to help people living with Long COVID who may have ongoing heart or lung problems. The model involves three parts:\n\n1. Screening: A simple assessment to identify people most likely to benefit from further care, based on symptoms and activity levels.\n2. Clinical review: A thorough check of heart and lung health conducted remotely via telehealth.\n3. Personalised exercise program: A tailored program to help improve fitness and reduce time spent sitting, delivered entirely via telehealth.\n\nThe main thing this study is measuring is whether participants can walk further after 6 months compared to when they started (measured using a 6-minute walk test), which correlates well with an individuals ability to complete normal daily functions. The study will also look at quality of life, mental health, physical activity, heart function, and hospital visits over 2 years.\n\nThe study is designed with input from patients and healthcare providers to ensure it meets real-world needs. All care is delivered remotely, meaning participants can take part from home anywhere in Australia.",[30],[30,118,119,120,121,122,123],"Exercise","PERCEIVE-Outreach","PERCEIVE","Australia","Rural Health","Cardiovascular","2026-06-16",{"date":126,"type":38},"2026-06-22",{"date":128,"type":38},"2026-04-01",{"date":130,"type":21},"2029-04-01",{"name":132,"class":45},"University of Tasmania",2,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":46},"100586841","phase-1-pet-imaging-of-cyclooxygenase-1-in-participants-with-neurological-manifestations-of-post-acute-sequelae-of-sars-cov-2-infection-pasc-100586841","NCT06920628","PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)","* INCLUSION CRITERIA:\n\nPatients: To be eligible for this study, Neuro-PASC participants must meet all of the following criteria:\n\n* Aged 18 to 70 years of age.\n* Participants must be in good general health as evidenced by medical history and physical examination.\n* Each participant must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.\n* Participants must have undergone a screening assessment under protocol #000089, Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health or #000711 Immunotherapy for Neurological Post-Acute Sequelae of SARSCoV-2 (INPASC) and determined to have neuro-PASC.\n* Participants must have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Participants must agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers: To be eligible to participate in this study, healthy volunteers must meet all of the following criteria:\n\n* Aged 18 to 70 years of age.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and\u002For testing.\n* Participants must be at least six weeks out since the onset of SARS-CoV-2 symptoms with no fever for at least one week.\n* Participants must report having at least one prior SARS-CoV-2 infection.\n* Be enrolled in 01M0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17M0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies .\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nParticipants with Neuro-PASC who meet any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing based on individual clinical judgement. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two times the upper limit or lower values, as per the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL.\n* Participants should not have taken Non-Steroidal Anti-Inflammatory Drug (NSAID)s for two weeks prior to each PET scan. Corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g. methotrexate) must not have been taken within one month prior to each PET scan.\n* Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs daily life functions.\n* Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits as determined by the study team.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours,including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n* Pregnancy or Breastfeeding Women.\n* HIV Infection.\n\nHealthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for two weeks prior to the PET scan. Corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g., methotrexate) must not have been taken within one month prior to the PET scan.\n* Participants with an active SARS-CoV-2 infection.\n* Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs daily life functions.\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n* Pregnancy or Breastfeeding Women.\n* HIV Infection.",true,"70 Years",{"count":143,"type":21},60,[24],"Background:\n\nSARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain. These include headaches; loss of taste and smell; sleep problems; thinking problems; depression; and anxiety. Researchers want to know if a tracer (a substance that is injected into a person s body before an imaging scan) can help identify inflammation in people with these brain disorders.\n\nObjective:\n\nTo see if a radioactive tracer (\\[11C\\]PS13) can highlight brain inflammation in those who had COVID-19 but still have symptoms that affect the brain.\n\nEligibility:\n\nAdults aged 18 to 70 years with post COVID-19 brain disorders who are enrolled in protocol 000089 or 000711. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits.\n\nParticipants will be screened. They will have blood tests and a test of their heart function.\n\nThey will have imaging scans:\n\nMagnetic resonance imaging (MRI): They will lie on a table that slides into a metal tube. Pictures will be taken of the brain.\n\nPositron emission tomography (PET): A needle attached to a thin tube will be inserted into a vein in the arm. The tracer will be injected through the tube. Another needle attached to a thin tube will be inserted into the wrist or inside of the elbow of the other arm to draw blood. They will lie still on a bed while a machine captures images of their brain. The scan will last about 2 hours.\n\nStudy involvement is 11 to 14 weeks....",[30,147],"Post Acute Sequelae of COVID-19",[149,150,151,152],"Inflammation","COVID","SARS","Neuro-PASC",{"date":154,"type":38},"2026-06-17",{"date":156,"type":38},"2025-06-18",{"date":158,"type":21},"2029-02-22",{"name":160,"class":161},"National Institute of Mental Health (NIMH)","NIH",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":46},"100590950","phase-2-a-multi-center-individually-randomized-double-blind-placebo-controlled-parallel-group-superiority-trial-to-evaluate-the-efficacy-of-the-combination-of-maraviroc-and-atorvastatin-for-the-treatment-of-subjects-with-long-covid-100590950","NCT06974084","A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID","IMPACT-LC","Inclusion Criterial\n\n1. ≥ 18 and ≤ 65 years of age at the time of consent\n2. Meets WHO-defined post-COVID-19 condition (WHO definition: 'Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time).\n3. One or more new onset symptoms that persisted for greater than 6 months after the diagnosis of acute COVID-19 infection. These symptoms include: cognitive impairment (brain fog), migraines, post-exertional malaise (PEM), myalgias, arthralgias, severe fatigue, tachyarrhythmias, postural orthostatic tachycardia syndrome (POTS), and shortness of breath. The previous COVID-19 infection should be documented in the form of a positive PCR laboratory test and\u002For medical records from a healthcare provider. The Long-COVID diagnosis should be documented in the medical records by a healthcare provider.\n4. Negative Lyme screen, as measured by the AcuDart test.\n5. Epstein-Barr Virus (EBV) DNA negative (centrally assessed).\n6. A long hauler index (LHI) of \\>0.71\n7. A PROMIS Fatigue 10a T-score score \\> 55\n8. Participants of childbearing potential should be surgically sterilized or post-menopausal or must agree to take effective contraceptive measures during the study period. Adequate methods of birth control include: condoms, male or female, with or without a spermicide; diaphragm or cervical cap with spermicide; intrauterine device; any of the methods that require a prescription (such as contraceptive pills or path) or a male partner who has previously undergone vasectomy.\n9. Participant is willing and able to participate in the study and comply with all study requirements.\n10. Participant provided signed and dated IRB approved informed consent prior to initiation of any study procedures.\n11. Participant is able to read and understand English.\n\nExclusion Criteria\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Participation in another therapeutic clinical trial in the past 2 months.\n2. History of allergy or anaphylaxis or allergic reaction to any component of atorvastatin and\u002For maraviroc.\n3. Uncontrolled hypothyroidism as defined as thyroid-stimulating hormone (TSH) and\u002For free thyroxine (FT4) values outside the local laboratory reference range at screening, or a change in thyroid hormone replacement dose within 6 weeks prior to screening.\n4. Pre-COVID history of autoimmune conditions, migraines, neuropathy, inflammatory bowel disease (IBD), obsessive-compulsive disorder (OCD), or fatigue duration for ≥5 years, EBV infection, Lyme disease, fibromyalgia, arthritis, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD G3a or greater), chronic heart failure (CHF), arrhythmias, bleeding disorders, and anticoagulation therapy.\n5. Presence of other conditions or differential diagnosis that better explains the symptoms of the patient than the suspected long COVID, in the opinion of the investigator.\n6. Hepatic impairment, defined as Child-Pugh Score 7-9 (Class B) or greater.\n7. Active\u002Facute infectious diseases like tuberculosis, human immunodeficiency virus infection (HIV), cytomegalovirus (CMV), (vector based) Lyme, EBV, hepatitis B virus (HBV), hepatitis C virus (HCV).\n8. Ongoing immunosuppressive therapy, such as cyclosporine A (CsA).\n9. Use of statins within 6 months of randomization.\n10. Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir, or lipid-modifying doses (\\>1 gram\u002Fday) of niacin.\n11. AST:ALT ratio\\>1.5\n12. Elevations in IL-8 (\\>21 (pg\u002Fml) and or IL-13 (\\>6.1 pg\u002Fml) (centrally assessed with IncellKINE panel).\n13. Pregnant or breastfeeding\n14. History of substance use disorder (including alcohol use disorder or cannabis use disorder per DSM-5 criteria) within 3 months of enrollment, OR current hazardous alcohol use as defined by:\n\n    * Self-reported consumption \\>14 drinks\u002Fweek (males) or \\>7 drinks\u002Fweek (females), OR\n    * Binge drinking (≥5 drinks on one occasion for males, ≥4 for females) ≥1 time per week, OR\n    * Clinical judgment that alcohol use would interfere with study compliance or safety\n15. Subjects with risk factors for myocardial ischemia\u002Finfarction, including but not limited to those with a prior history of MI, stroke, unstable angina,\n16. Any significant disease or disorder, which, in the opinion of the Investigator, may either put the participants at risk\n17. Azole antifungals (ketoconazole or itraconazole are not allowed) or macrolide antibiotics (clarithromycin is not allowed)\n18. History of use of maraviroc and\u002For atorvastatin for the off-label treatment of Long COVID.\n\n    Prohibited concomitant medications\n19. Any statins within 6 months of randomization and between randomization and the participant's scheduled final visit\n20. Other systemically administered drugs with significant immunosuppressive activity, such as azathioprine, tacrolimus, cyclosporine, methotrexate, or cytotoxic chemotherapy between randomization and the participant's scheduled final visit\n21. Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including:\n\n    1. clarithromycin\n    2. cobicistat\n    3. elvitegravir\u002Fritonavir\n    4. itraconazole\n    5. ketoconazole\n    6. nefazodone\n    7. protease inhibitors (except tipranavir\u002Fritonavir)\n    8. telithromycin\n22. Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis:\n\n    1. cyclosporine or gemfibrozil\n    2. tipranavir plus ritonavir or glecaprevir plus pibrentasvir\n    3. niacin (≥1 gram\u002Fday niacin)",{"count":170,"type":21},252,[90,172],"PHASE3","The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 3 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.",[30],[176,177],"Long Covid","Post-COVID syndrome (PCS)",{"date":179,"type":38},"2026-06-18",{"date":181,"type":21},"2026-07-15",{"date":183,"type":21},"2027-05",{"name":185,"class":186},"HealthBio, Inc.","INDUSTRY",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":46},"100527014","water-based-activity-to-enhance-recovery-in-long-covid-19-100527014","NCT06142253","Water-based Activity to Enhance Recovery in Long COVID-19","Water-based Activity to Enhance Recovery in Long COVID","Inclusion Criteria:\n\n* Veterans, age 18 to 89, of any racial or ethnic group\n* Previous COVID-19 infection at least 6 months after diagnosis documented in clinical record\n* Persistent neurological symptoms (e.g., \"brain fog\", cognitive impairment) occurring within 3 months of onset of COVID-19 infection and lasting at least 8 weeks in duration\n* Visual and auditory acuity to allow neuropsychological testing\n* Willingness to participate in clinical trial for 8 months\n* Approval by Primary Care Provider to participate in water-based physical exercise\n\nExclusion Criteria:\n\nPsychiatric Exclusions\n\n* Current, uncontrolled severe psychotic disorder determined by the Mini International Neuropsychiatric Interview (MINI) Medical Exclusions\n* History of neurological (e.g., multiple sclerosis, seizure disorder, stroke,) neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease) or system illness affecting CNS function (e.g., liver failure, kidney failure, congestive heart failure, systemic cancer) occurring before COVID-19 diagnosis\n* Current severe cardiac disease (e.g., uncontrolled atrial fibrillation, defined as mean 24 hour heart rate \\>85 beats\u002Fmin, or 24 hour maximal ventricular rate \\>150 beats\u002Fmin; uncontrolled ventricular arrhythmias, defined as recurrent ventricular tachycardia \\>3 beats in succession, or 24 hour PVC count \\>20%; active pericarditis or myocarditis; Class III\u002FIV heart failure and \u002F or ejection fraction \\\u003C 20%; thrombophlebitis; pulmonary disease with a drop in O2 Sat with exercise to 90% without oxygen; embolism within past 6 months)\n* Inability to participate in an exercise stress test\n* Inability to read, verbalize understanding and voluntarily sign the Informed Consent","89 Years",{"count":196,"type":21},50,[59],"This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neurological symptoms of long-COVID. This is a two-phased trial: 1) an exercise phase and 2) a cognitive training phase. The exercise phase will be an aquatic based exercise program. A combination exercise + memory training programs designed for persons with cognitive impairment have significantly improved memory more than other single intervention groups (exercise only, cognitive training only) and given the success of combination training programs with healthy adults, it is important to adapt these programs for persons with neurological symptoms of long-COVID.",[30],[201,202,118,203,204],"Post-Acute COVID-19 Syndrome","Cognitive Training","Veterans","Mental Fatigue",{"date":179,"type":38},{"date":207,"type":38},"2024-12-01",{"date":209,"type":21},"2026-12-31",{"name":211,"class":212},"VA Office of Research and Development","FED",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":46},"100563295","non-invasive-treatment-for-long-covid-post-covid-19-condition-brain-fog-100563295","NCT06614309","Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog","Pilot Study to Investigate Possible Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog","Inclusion criteria:\n\n* English speaking\n* Diagnosis of Long COVID\n\nExclusion criteria:\n\n* Any history of:\n\n  * Coronary artery dissection or aortic dissection\n  * Neurological disease (e.g. dementia, Alzheimer's disease, or other brain-related disease)\n  * Cerebrovascular disease or stroke\n  * Aneurysm\n* If currently has:\n\n  * Moderate-severe chronic obstructive pulmonary disease\n  * Uncontrolled moderate-severe asthma\n  * Moderate-severe bronchiectasis\n  * Moderate-severe interstitial lung disease, requiring the use of supplemental oxygen\n  * A necessity to use supplemental oxygen, for any reason\n  * New or worsening symptoms (decompensation) of heart failure\n  * Right heart disease due to chronic pulmonary disease\u002Fsleep apnea\n  * Uncontrolled myocardial ischemia or angina\n  * Uncontrolled heart arrhythmias\n  * Heart or lung infection (e.g. myocarditis or pericarditis)\n  * Left main coronary artery stenosis\n  * Moderate-severe aortic stenosis\n  * Pulmonary embolism, pulmonary infarction, or other blood clots\n  * Severe respiratory disease\n  * Chronic kidney disease\n  * Chronic liver disease\n* Females of childbearing potential will complete a urine pregnancy test at their baseline visit to rule out pregnancy\n* BMI \\>40\n* Study staff unable to obtain adequate signal for cerebral blood flow",{"count":221,"type":21},45,[59],"This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.",[30],[226,227,228,67],"brain fog","brain blood flow","heart rate variability","2026-06-03",{"date":231,"type":38},"2026-06-05",{"date":233,"type":38},"2024-09-24",{"date":235,"type":21},"2026-12",{"name":237,"class":45},"Mayo Clinic",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":16,"minAge":245,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100637640","phase-2-evaluating-the-safety-and-efficacy-of-pnmr-as-treatment-for-long-covid-100637640","NCT07627815","Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID","Phase II, Proof of Concept, Open-Label, Randomized-Controlled Trial Evaluating the Efficacy and Safety of PARAGON Novel Metabolic Regulator Formula (PNMR) in the Management of Long COVID","Inclusion Criteria: The patient must meet all the following criteria to be enrolled in the study:\n\n1. ≥19 years of age.\n2. Negative COVID-19 test for a minimum of four (4) weeks prior to enrollment in the study.\n3. Confirmed COVID-19 diagnosis by Polymerase chain reaction (PCR) test, antibody test, or clinical diagnosis more than four (4) weeks prior to enrollment in the study.\n4. Long COVID diagnosis according to the WHO criteria, specifically the continuation or development of new symptoms three months after the initial SARS-COV-2 infection, with these symptoms lasting for more than two months with no other explanation.\n5. For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use contraceptive (consistent with local regulations) during the study period. Approved contraceptive methods include contraceptive pills or patches, hormonal implants, intrauterine device (IUD), diaphragm or cervical cap with spermicide, and condos with spermicide.\n\n   Note: If participant become pregnant during the study, they must stop taking the study products immediately and inform the study investigator.\n6. Patient agrees to stop taking any over the counter supplements, vitamins, or natural products as well as any of the prohibited medications during the study.\n7. Patient agrees not to use medications affecting directly (or potentially) the objectives of the study such as fatigue and cognitive function during the study.\n8. Willing to adhere to the study diet and exercise recommendations to the best of the patient's ability.\n9. Willing to complete the 6MWT.\n10. Willing to complete the patient self-administered questionnaires and diaries.\n11. Signed informed consent form by any patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal\u002Fauthorized representatives.\n\nExclusion Criteria:\n\n1. Subject is a female who is breastfeeding or pregnant or trying to conceive.\n2. Subject with a vegetarian diet or not able to follow the dietary guidelines.\n3. Known hypersensitivity to PNMR or its ingredients.\n4. Participating in other drug clinical trials (participation in COVID-19 antiviral trials may be permitted if approved by sponsor).\n5. Any condition that in the opinion of the investigator participation in the trial increases the risk to the patient.\n6. 4 weeks or more of consecutive daily supplement use of 5000 IUs Vitamin D \u002F day and\u002For 50mg Zinc (without copper) \u002F day within 4 weeks of Day 0.\n7. Use of any medications or treatments for which treatment with PNMR is counter-indicated.\n8. Subject is not able to swallow a larger number of capsules.\n9. Any condition that in the opinion of the investigator would confound the study results or would prevent the patient to complete the study.\n10. Any patient for whom vitamin D3 (cholecalciferol) is contraindicated per the following patient situations:\n\n    1. Hypersensitivity to vitamin D, any of its analogues and derivatives or to any ingredient in the formulation\n    2. Hypercalcemia and\u002For hypercalciuria\n    3. Nephrolithiasis (renal calculi)\n    4. Severe renal impairment (eGFR \\\u003C30)\n    5. Malabsorption syndrome\n    6. Abnormal sensitivity to the toxic effects of vitamin D\n    7. Sarcoidosis\n    8. Hypervitaminosis D","19 Years",{"count":247,"type":21},82,[90],"This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \\& Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation.\n\nPatients will be assessed in the clinic at screening\u002Fbaseline, 3 and 6 weeks while on treatment, and by telephone at 4 weeks post-treatment.\n\nAll patients will be asked to fill in a diary to record their daily treatment dosage when being treated with PNMR + SOC or with SOC alone. Primary objective: To evaluate the efficacy of PNMR + (SOC) vs. SOC in the treatment and management of patients with long COVID.",[30],[252,253,254,255],"Covid-19","Brain Fog","Chronic Fatigue","Post Exertional Malaise","2026-06-02",{"date":258,"type":38},"2026-06-04",{"date":260,"type":38},"2026-05-20",{"date":262,"type":21},"2026-12-26",{"name":264,"class":186},"ParagonClinicals Inc.",4,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":46},"100626451","long-term-health-effects-of-previous-coronavirus-disease-2019-covid-19-in-patients-undergoing-preoperative-anesthesia-evaluation-100626451","NCT07435805","Long-Term Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Undergoing Preoperative Anesthesia Evaluation","Long-Term Clinical and Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Presenting for Preoperative Anesthesia Evaluation","Inclusion Criteria:\n\n* Age ≥18 years\n\nPresentation to the preoperative anesthesia clinic\n\nSelf-reported history of laboratory-confirmed COVID-19 infection\n\nAbility to provide informed consent\n\nWillingness to complete the post-COVID clinical questionnaire\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n\nNo history of COVID-19 infection\n\nRefusal to participate or incomplete questionnaire\n\nCognitive impairment or communication difficulties preventing reliable data collection",{"count":274,"type":21},400,"OBSERVATIONAL","The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in persistent health problems in a significant proportion of individuals after recovery from the acute infection. These long-term manifestations, commonly referred to as post-COVID-19 condition or long COVID, may involve respiratory, cardiovascular, neurological, psychological, and general health domains. Understanding these sequelae is particularly important in patients undergoing preoperative anesthesia evaluation, as residual symptoms may influence perioperative risk assessment and clinical decision-making. This cross-sectional observational study aims to evaluate the long-term clinical and health effects of previous COVID-19 infection in adult patients presenting to the preoperative anesthesia clinic. Patients aged 18 years and older who report a history of confirmed COVID-19 infection will be included. Clinical data related to the acute infection period (disease severity, hospitalization, intensive care unit (ICU) admission, oxygen therapy, and radiological findings) will be retrospectively obtained from hospital records. At the time of preoperative assessment, participants will complete a structured post-COVID-19 clinical questionnaire to evaluate persistent symptoms across multiple organ systems. The study seeks to determine the prevalence and characteristics of long-term post-COVID-19 symptoms and to explore potential associations between acute disease severity and ongoing health complaints. No additional medical intervention will be performed as part of this research.",[278,30,279],"Post-COVID Condition","Sequelae of COVID-19",[278,281,282,283],"Preoperative Assessment","Cross-Sectional Study","COVID-19 Sequelae",{"date":258,"type":38},{"date":286,"type":38},"2025-12-01",{"date":288,"type":21},"2026-06-20",{"name":290,"class":45},"Elazıg Fethi Sekin Sehir Hastanesi",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":313,"locationsCount":314},"100571568","phase-2-taurine-supplementation-in-long-covid-100571568","NCT06721949","Taurine Supplementation in Long COVID","Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to randomization.\n3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.\n5. Lingering symptoms from COVID-19 present at the time of randomization.\n6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator (refer to Section 5 Contraception of the Master Protocol, and Section 13.1.2 of this protocol).\n7. Must be able to provide informed consent and both willing and able to comply with study requirements.\n8. Medications prescribed for treating fatigue or cognition have been discontinued for four weeks prior to enrolment and randomization. These include sildenafil, modafinil (Provigil), or armodafinil (Nuvigil), guanfacine, N-acetyl cysteine, and stimulant medications used for attention-deficit hyperactivity disorder (ADHD).\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.\n2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.\n3. Contraindications to the study intervention.\n4. Currently already on study intervention(s).\n5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted).\n6. Currently pregnant or breastfeeding.\n7. The participant is currently enrolled in another clinical trial to treat neurocognitive symptoms in LC.",{"count":299,"type":21},300,[90,172],"The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.",[30],[304,150,30,305,306],"Taurine","randomized trial","neurocognitive symptoms","2026-05-22",{"date":309,"type":38},"2026-05-27",{"date":311,"type":38},"2025-11-18",{"date":74,"type":21},{"name":103,"class":45},5,{"id":316,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":327,"leadSponsor":328,"locationsCount":46},"100610200","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* Hemoglobin no less than 0.5 g\u002FdL below the lower limit of the sex specific reference range\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek)\n* Active use of illicit drugs\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding",{"count":20,"type":21},[24],"The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.\n\nThis study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characterization of endogenous LH secretion before and after kisspeptin administration. This frequency of blood sampling is required to define the features of LH pulses.",[27,28,29,30],[32,28,29,33,30],"2026-05-16",{"date":325,"type":38},"2026-05-19",{"date":40,"type":38},{"date":42,"type":21},{"name":44,"class":45},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":46},"100637180","phase-2-sars-cov-2-and-herpesvirus-inhibition-for-ending-long-covid-dysfunction-100637180","NCT07597902","SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction","SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction (SHIELD)","SHIELD","Inclusion Criteria:\n\n* 18-65 years of age at the time of study entry\n* Diagnosed with Long COVID\n* Individuals of child-bearing potential must have a negative serum pregnancy test at screening and agree to on-site urine pregnancy testing at all subsequent study visits\n* A urine drug screen performed at the Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed amphetamines and opioids\u002Fopiates.\n* Those with mild to moderate depression should be clinically stable for three months, without risk of suicidal ideation or behavior.\n\nExclusion Criteria:\n\n* Breastfeeding, pregnant, or planning to become pregnant during the next six months.\n* In the opinion of the Investigator, any clinically significant, uncontrolled, or unstable medical or surgical condition that could affect the individual's ability to participate in the study or potentially compromise their well-being while enrolled in the study.\n* In the opinion of the Investigator or based on results of the HADS, evidence of a clinically significant psychiatric disorder, e.g., severe, unstable or poorly controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe alcohol use disorder; substance use disorder other than mild cannabis use disorder; or any history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder.\n* Currently meeting criteria for ME\u002FCFS at the pre-screening or screening visit, or a prior confirmed diagnosis of ME\u002FCFS within the last 5 years. This may be determined as part of the initial screening call or visit.\n* Any anticipated need for surgery that in the opinion of the Principal Investigator or Sub-I might confound results or interfere with the participant's ability to comply with the protocol.\n* Symptomatic and\u002For otherwise clinically significant cardiac disease\n* Acute non-COVID systemic infection (e.g., HIV, hepatitis) or other active viral or bacterial infection during the screening\u002Fwashout period or at the Baseline visit.\n* Currently receiving chronic systemic corticosteroids (\\>5 mg prednisone daily, or equivalent)\n* Routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid, phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Participants on these medications should not be screened.\n* Uncontrolled sleep apnea.\n* Use of chronic nucleoside analog antiviral suppression therapy within one month of the Screening Visit or requiring on average more than one acute treatment course every two months.\n* Current use of celecoxib either alone or in combination with valacyclovir or famciclovir\n* In the opinion of the Investigator, evidence of current drug or alcohol abuse or dependency, or history of abuse or dependence during the preceding 12 months.\n* The participant has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y or other bypass procedure).\n* Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel movements.",{"count":338,"type":21},150,[90],"The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).",[342,30],"Post-acute Sequelae of COVID-19","2026-05-14",{"date":325,"type":38},{"date":346,"type":21},"2026-06-01",{"date":348,"type":21},"2028-06-30",{"name":350,"class":45},"Icahn School of Medicine at Mount Sinai",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":46},"100602455","phase-2-a-study-to-examine-anktiva-for-the-treatment-of-covid-19-100602455","NCT07123727","A Study to Examine Anktiva for the Treatment of COVID-19.","Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C 70 years.\n* History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and\u002For a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Those with only suspected but unconfirmed infections are not eligible for this study.\n* Clinical evidence of Long COVID, as confirmed by the Investigator's assessment.\n\n  1. At least 2 symptoms or at least 1 severe symptom as assessed by the study team (see list) that are new or worsened since the time of a SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the PI. At least 2 symptoms from those listed here must be present: systemic symptoms (eg, fatigue, chills, post-exertional malaise), neurocognitive symptoms (eg, trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia symptoms, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (eg, chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (eg, muscle aches, joint pain), gastrointestinal symptoms (eg, nausea, diarrhea). Although other symptoms (eg, skin rash, hair loss, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least 2 core symptoms listed above must be present. Note: the 2 symptoms can be from within the same category (for example, brain fog and headache) AND\n  2. Symptoms must have been present for at least 60 days prior to screening. Symptoms that wax and wane must have been initially present at least 60 days prior to screening AND\n  3. Symptoms must be reported to be at least somewhat bothersome and to have an impact on quality of life and\u002For everyday functioning AND\n  4. At least 90 days have elapsed since the most recent suspected or confirmed SARS-CoV-2 infection and the time of screening. Note: suspected infections will be determined based upon assessment by the study Investigators.\n* Not currently hospitalized.\n* Body mass index (BMI) 18 to 50 kilograms\u002Fmeter squared (kg\u002Fm2), inclusive, at the time of screening.\n* In otherwise stable health, as assessed by the Investigator within 28 days prior to screening, based on medical history, physical examination, laboratory findings, and vital signs.\n* For male participants,\n\n  a. Participants with partners that are WOCBP are strongly advised to inform their partners and must agree to use effective contraception from study entry (defined as INT1) through 7 months after the last dose of study intervention. Participants with pregnant partners must agree to use condoms during vaginal intercourse from study entry (defined as INT1) through 14 days after the last dose of study intervention administration.\n* For female participants,\n\n  a. A female participant who engages in sexual intercourse with male partners is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies: i. Is not a WOCBP OR ii. All of the following apply:\n  1. Is a WOCBP and is using a contraceptive method from - 21 days from study entry (defined as INT1), during the study intervention period, and for at least 7 months after the last study intervention administration.\n  2. A WOCBP must have a negative urine pregnancy test within 24 hours prior to all doses of study intervention. If a urine pregnancy test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test must be negative.\n* Willingness and ability to comply with the study protocol. This includes reliable transportation and sufficient time to attend all visits.\n* Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Previously received a SARS-CoV-2 antiviral or monoclonal antibody 30 days prior to planned INT1 or plan to receive such treatment before exiting the study.\n* Plans to receive any investigational or approved vaccine or booster for SARS-CoV-2 within 14 days prior to plan to receive such treatment before exiting the study.\n* History of autoimmune disease including, but not limited, to celiac disease, rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.\n* Active cardiovascular disease, defined as known prior:\n\n  1. Myocardial infarction within 90 days of screening; OR\n  2. Coronary artery bypass procedure within 90 days of screening; OR\n  3. Current heart failure with reduced ejection fraction (\\\u003C45%); OR\n  4. Current pulmonary arterial hypertension.\n* Known stroke within 3 months prior to planned INT1.\n* Known active bacterial, fungal, viral, or other infection besides SARS-CoV-2 requiring treatment within the 14 days prior to INT1 and meeting criteria for systemic involvement upon review by the PI.\n* Major surgery within 3 months prior to planned INT1 or planned major surgery during the first 75 days following planned INT1.\n* History of unplanned hospitalization for \\>24 hours within 28 days prior to Screening.\n* Active or prior Hepatitis B (Hep B) infection (defined as Hep B core antibody (cAb) and\u002For Hep B surface antigen (sAg) positive. Note: Prior hepatitis B is exclusionary even in the absence of ongoing infection.\n* Active Hepatitis C (Hep C) infection (defined as Hep C Ab positive or indeterminate with detectable Hep C RNA). Note: Those with cured Hep C (Ab positive or indeterminate but negative Hep C RNA) will remain eligible.\n* Laboratory abnormalities including:\n\n  1. ANC \\\u003C 1,500 per mm3\n  2. Platelet count \\\u003C100,000 per mm3\n  3. Hemoglobin \\\u003C 9 d\u002FdL\n  4. Baseline AST or ALT \\> 1.5 × ULN\n  5. CrCl \\\u003C 50 (estimated glomerular filtration rate)\n* Known or suspected HIV infection.\n* End stage kidney disease requiring dialysis.\n* History of Type I or Type 2 Diabetes mellitus requiring systemic medication or insulin.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Moderate or severe immunocompromise, includes the following: (a) receiving active treatment for solid tumor or hematologic malignancy, including use of systemic chemotherapy for treatment of cancer within the year prior to screening, (b) prior solid-organ transplant with active immunosuppressive therapy, (c) CAR-T cell therapy or hematopoietic cell transplant, on immunosuppressive therapy or transplant within the prior 2 years, (d) primary immunodeficiency syndromes, advanced or untreated HIV infection (see above), (f) on active high-dose corticosteroids (ie, ≥ 20mg prednisone or equivalent daily per day for ≥ 2 weeks).\n* Known prior diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS), preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known prior diagnosis of dysautonomia, preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known allergy to any components used in the formulation of the intervention.\n* History of anaphylaxis or similar significant allergic reaction to prescription or non-prescription drugs or food products. Similarly, the presence of severe atopic conditions as assessed by the PI represents a significant risk for allergic reaction.\n* Participation in a clinical trial with receipt of an investigational product within 28 days prior to planned INT1, except for exploratory PET imaging studies related to Long COVID.\n* Current alcohol or illicit drug use as determined by the Investigator to preclude participation.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.",{"count":20,"type":21},[90],"This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.",[30,362,363],"Long COVID Syndrome","Long Covid 19","2026-05-08",{"date":366,"type":38},"2026-05-13",{"date":368,"type":38},"2025-09-04",{"date":370,"type":21},"2026-07",{"name":372,"class":186},"ImmunityBio, Inc.",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":46},"100601249","phase-2-a-study-to-assess-anktiva-in-patients-with-long-covid-19-100601249","NCT07108036","A Study to Assess Anktiva in Patients With Long Covid-19.","Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.","INTERRUPT_LC","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C 70 years.\n* Enrolled or willing to enroll and complete at least 1 visit in the UCSF Long-term Impact of Infection with Novel Coronavirus study. Any adult who has been infected with SARS-CoV-2 or has ever received or is eligible to receive a SARS-CoV-2 vaccination, and who is able to provide written informed consent, is eligible to participate in LIINC.\n* History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and\u002For a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Written proof of the test will be requested but is not required as long as the participant attests to the positive test. Those with only suspected but unconfirmed infections are not eligible for this study.\n* Clinical evidence of Long COVID, as confirmed by the Investigator's assessment.\n\n  1. At least 2 symptoms or at least 1 severe symptom as assessed by the study team (see list) that are new or worsened since the time of a SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the PI. At least 2 symptoms from those listed here must be present: systemic symptoms (eg, fatigue, chills, post-exertional malaise), neurocognitive symptoms (eg, trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia symptoms, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (eg, chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (eg, muscle aches, joint pain), gastrointestinal symptoms (eg, nausea, diarrhea). Although other symptoms (eg, skin rash, hair loss, mental health symptoms, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least 2 core symptoms listed above must be present. Note: the 2 symptoms can be from within the same category (for example, brain fog and headache) AND\n  2. Symptoms must have been present for at least 60 days prior to screening. Symptoms that wax and wane must have been initially present at least 60 days prior to screening AND\n  3. Symptoms must be reported to be at least somewhat bothersome and to have an impact on quality of life and\u002For everyday functioning AND\n  4. At least 90 days have elapsed since the most recent suspected or confirmed SARS-CoV-2 infection and the time of screening. Note: suspected infections will be determined based upon assessment by the study Investigators.\n* Not currently hospitalized.\n* Body mass index (BMI) 18 to 50 kilograms\u002Fmeter squared (kg\u002Fm2), inclusive, at the time of screening.\n* In otherwise stable health, as assessed by the Investigator within 28 days prior to screening, based on medical history, physical assessment, laboratory findings, and vital signs.\n* For male participants,\n\n  a. Participants with partners that are women of childbearing potential (WOCBP) are strongly advised to inform their partners and must agree to use effective contraception from study entry (defined as INT1) through 7 months after the last dose of study intervention. Effective methods of contraception are described in Appendix 2. Participants with pregnant partners must agree to use condoms during vaginal intercourse from study entry (defined as INT1) through 14 days after the last dose of study intervention administration. Participants assigned male sex at birth must agree to refrain from sperm donation from study entry through 14 days after the last dose of study intervention administration.\n* For female participants,\n\n  a. A female participant who engages in sexual intercourse with male partners is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies: i. Is not a WOCBP OR ii. All of the following apply:\n  1. Is a WOCBP and is using a contraceptive method that is effective as described in Appendix 1 from -21 days from study entry (defined as INT1), during the study intervention period, and for at least 7 months after the last study intervention administration. She must also agree not to donate her eggs (ova, oocytes) for the purpose of reproduction from study entry (defined as INT1), during the study intervention period, and for at least 7 months after the last study intervention administration.\n  2. A WOCBP must have a negative urine pregnancy test within 24 hours prior to all doses of study intervention. If a urine pregnancy test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test must be negative.\n* Willingness and ability to comply with the study protocol. This includes reliable transportation and sufficient time to attend all visits.\n* Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Previously received a SARS-CoV-2 antiviral or monoclonal antibody 30 days prior to planned INT1 or plan to receive such treatment before exiting the study.\n* Plans to receive any investigational or approved vaccine or booster for SARS-CoV-2 within 14 days prior to planned INT1 or before FU2.5 following planned INT1.\n* History of autoimmune disease including, but not limited to, celiac disease, rheumatoid arthritis, psoriasis, and inflammatory bowel disease.\n* Active cardiovascular disease, defined as known prior:\n\n  1. Myocardial infarction within 90 days of screening; OR\n  2. Coronary artery bypass procedure within 90 days of screening; OR\n  3. Current heart failure with reduced ejection fraction (\\\u003C45%); OR\n  4. Current pulmonary arterial hypertension.\n* Known stroke within 3 months prior to planned INT1.\n* Known active bacterial, fungal, viral, or other infection besides SARS-CoV-2 requiring treatment within the 14 days prior to INT1 and meeting criteria for systemic involvement upon review by the PI. Note: Mild or limited infections such as uncomplicated urinary tract or yeast infections, sexually transmitted infections, and mild dermatophyte infections may be reviewed with the Safety Monitoring Committee chair but are not exclusionary.\n* Major surgery within 3 months prior to planned INT1 or planned major surgery during the first 75 days following planned INT1.\n* History of unplanned hospitalization for \\>24 hours within 28 days prior to Screening.\n* Active or prior Hepatitis B (Hep B) infection (defined as Hep B core antibody (cAb) and\u002For Hep B surface antigen (sAg) positive. Note: Prior hepatitis B is exclusionary even in the absence of ongoing infection.\n* Active Hepatitis C (Hep C) infection (defined as Hep C Ab positive or indeterminate with detectable Hep C RNA). Note: Those with cured Hep C (Ab positive or indeterminate but negative Hep C RNA) will remain eligible.\n* Laboratory abnormalities including:\n\n  1. ANC \\\u003C 1,500 per mm3\n  2. Platelet count \\\u003C100,000 per mm3\n  3. Baseline AST or ALT \\> 1.5 × ULN\n  4. Hemoglobin \\\u003C 9 d\u002FdL\n  5. CrCl \\\u003C 50 (estimated glomerular filtration rate)\n  6. ALC \\\u003C 1,000 per mm3\n* Known or suspected HIV infection.\n* End stage kidney disease requiring dialysis.\n* History of Type I or Type 2 Diabetes mellitus requiring systemic medication or insulin.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Moderate or severe immunocompromise, according to the current National Institutes of Health (NIH) COVID-19 Treatment Guidelines as of March 6, 2023. The detailed list is in Appendix 2, and includes the following: (a) receiving active treatment for solid tumor or hematologic malignancy, including use of systemic chemotherapy for treatment of cancer within the year prior to screening, (b) prior solid-organ transplant with active immunosuppressive therapy, (c) CAR-T cell therapy or hematopoietic cell transplant, on immunosuppressive therapy or transplant within the prior 2 years, (d) primary immunodeficiency syndromes, advanced or untreated HIV infection (see above), (f) on active high-dose corticosteroids (ie, ≥ 20mg prednisone or equivalent daily per day for ≥ 2 weeks).\n* Known prior diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS), preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known prior diagnosis of dysautonomia, preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known allergy to any components used in the formulation of the intervention.\n* History of anaphylaxis or similar significant allergic reaction to prescription or non-prescription drugs or food products. Similarly, presence of severe atopic conditions as assessed by the PI represents significant risk for allergic reaction.\n* Participation in a clinical trial with receipt of an investigational product within 28 days prior to planned INT1, with the exception of exploratory PET imaging studies related to Long COVID.\n* Current alcohol or illicit drug use as determined by the Investigator to preclude participation.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.",{"count":382,"type":21},20,[90],"This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.",[30],{"date":387,"type":38},"2026-05-11",{"date":389,"type":38},"2025-11-14",{"date":391,"type":21},"2026-10",{"name":372,"class":186},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":409,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":419},"100564600","phase-3-randomized-double-blind-placebo-controlled-trial-evaluating-baricitinib-on-persistent-neurologic-and-cardiopulmonary-symptoms-of-long-covid-100564600","NCT06631287","Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)","REVERSE-LC","INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this investigation, an individual must meet all of the following criteria:\n\nCohort #1 (n=500):\n\n1. Evidence of personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study and was willing and able to consent to participation.\n2. Age ≥18 years old.\n3. Documented SARS-CoV-2 infection 6 or more months prior to screening, confirmed with acceptable documentation that includes (at minimum) their name, the date the test was taken (must be after January 2020), and details specifying that the positive test was for SARS-CoV-2 infection.\n4. Clinical evidence of Long COVID, as confirmed by the investigator's assessment:\n\n   a. At least one symptom (listed below) that is new or worsened since the time of SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the study clinicians (MD, DO, NP, PA, RN, or equivalent).\n\n   i. Systemic symptoms (e.g., fatigue, chills, post-exertional malaise), neurocognitive symptoms (e.g., trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia syndrome, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (e.g., chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (e.g., muscle aches, joint pain), gastrointestinal symptoms (e.g., nausea, diarrhea). Although other symptoms (e.g., skin rash, hair loss, mental health symptoms, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least one core symptoms listed above must be present.\n\n   b. Symptoms must be present for at least 6 months prior to screening. Symptoms that wax and wane must have been initially present at least 6 months prior to screening.\n\n   c. Symptoms must be reported to have an impact on quality of life and\u002For everyday functioning and to be at least somewhat bothersome.\n\n   d. Cognitive impairment present defined by having at least 20% positive items (answered subjectively worse or much worse) on the 41-item modified ECog questionnaire.\n\nCohort #2 (n=50):\n\n1. Evidence of personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study and was willing and able to consent to participation.\n2. Age ≥18 years old.\n3. Clinical diagnosis of COVID infection between January 2020 and September 1, 2021 (i.e., before home tests were widely available).\n\n   a. Clinical Criteria (Based on Council of State and Territorial Epidemiologists Standardized Surveillance Case Definition for COVID-19): i. At least two of the following symptoms: Fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s).\n\n   -OR- ii. At least one of the following symptoms: Cough, shortness of breath, or difficulty breathing.\n\n   -OR- iii. Severe respiratory illness with at least one of the following: clinical or radiographic evidence of pneumonia or Acute Respiratory Distress Syndrome (ARDS).\n\n   -AND- iv. No alternate more likely diagnosis\n4. Clinical evidence of Long COVID, as confirmed by the clinician's assessment:\n\n   a. At least one symptom (listed below) that is new or worsened since the time of SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the study clinicians (MD, DO, NP, PA, RN, or equivalent).\n\n   i. Systemic symptoms (e.g., fatigue, chills, post-exertional malaise), neurocognitive symptoms (e.g., trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia syndrome, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (e.g., chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (e.g., muscle aches, joint pain), gastrointestinal symptoms (e.g., nausea, diarrhea). Although other symptoms (e.g., skin rash, hair loss, mental health symptoms, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least one core symptoms listed above must be present.\n\n   b. Symptoms must be present for at least 6 months prior to screening. Symptoms that wax and wane must have been initially present at least 6 months prior to screening.\n\n   c. Symptoms must be reported to have an impact on quality of life and\u002For everyday functioning and to be at least somewhat bothersome.\n\n   d. Cognitive impairment present defined by having at least 20% positive items (answered subjectively worse or much worse) on the 41-item modified ECog questionnaire.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this investigation:\n\n1. Qualifying Long COVID symptoms cannot be explained by an infection-associated chronic condition diagnosed prior to the onset of Long COVID (e.g., ME\u002FCFS or other infection-associated chronic condition).\n2. Pre-existing cognitive impairment not exacerbated by COVID-19, including but not limited to syphilis, as determined by study clinicians (MD, DO, NP, PA, RN, or equivalent), which may include a review of participant's history and medical records.\n3. Severe cognitive, physical, or psychological disability preventing participation in the study, as determined by the investigator.\n4. Moderate or High risk of suicidality, as determined by the modified Columbia Suicide Severity Rating Scale (mC-SSRS).\n5. History of a major adverse cardiovascular event (MACE) within the 3 months prior to enrollment.\n6. Current use of baricitinib or other disease-modifying antirheumatic drug (DMARDs); however, DMARDs with minimal immunomodulatory effects (hydroxychloroquine, i.e., Plaquenil, steroids used for less than 2 weeks, minocycline), are not exclusionary.\n7. Known prior allergic reactions to components of the baricitinib.\n8. Previously randomized in this study or in the last 30 days have been in another study investigating baricitinib.\n9. Positive SARS-CoV-2 NAAT or rapid Antigen test in the 14 days prior to screening.\n10. Venous thromboembolism in the past 6 months prior to screening or felt to be at increased risk of thrombosis by the investigator.\n11. Malignancy or lymphoproliferative disorder not in remission for at least 5 years. Local non-melanoma skin cancers that are definitively managed are not exclusionary.\n12. Previous admission to an ICU for treatment of acute COVID-19 infection.\n13. Estimated glomerular filtration rate of \\\u003C 30 mL\u002Fmin\u002F1.73m2, as calculated using the CKD-EPI 2021 equation.\n14. Absolute Neutrophil Count (ANC) \\\u003C1000 cells\u002Fmm3, confirmed on repeat testing.\n15. Absolute Leukocyte Count (ALC) \\\u003C100 cells\u002Fmm3.\n16. Evidence of severe liver disease at the time of screening, defined as Bilirubin \\> 1.5 X ULN or AST or ALT \\> 2x ULN.\n17. Alkaline Phosphatase (ALP) ≥ 3x ULN.\n18. Creatine Phosphokinase (CPK) ≥ 3x ULN.\n19. Hemoglobin (HgB) \\\u003C 8 g\u002FdL, confirmed on repeat testing.\n20. Platelets \\\u003C100,000 cells\u002Fmm3, confirmed on repeat testing.\n21. Platelets \\>500,000 cells\u002Fmm3, confirmed on repeat testing.\n22. Total fasting cholesterol ≥ 280 mg\u002FdL, confirmed on repeat testing.\n23. Fasting LDL ≥ 180 mg\u002FdL, confirmed on repeat testing.\n24. Positive Hepatitis B surface antigen or Hepatitis B core antibody. Note: Individuals with a positive Hepatitis B core antibody will be excluded even in the presence of a positive Hepatitis B surface antibody due to the risk of reactivation.\n25. Positive for Hepatitis C at the time of Screening. Note: treated or cleared Hepatitis C is not exclusionary.\n26. Symptomatic herpes zoster infection (i.e., visible herpetic skin lesions of Zoster) within 3 months prior to study screening, or any history of disseminated\u002Fcomplicated herpes zoster or herpes simplex infection (e.g., VZV encephalitis).\n27. History of untreated latent tuberculosis infection (diagnosed with QuantiFERON-TB Gold Plus testing) or active tuberculosis whether treated or untreated. Note: those with a positive PPD who have a history of BCG vaccine and a negative QuantiFERON-TB Gold Plus test will remain eligible).\n28. History of current or recent (\\\u003C 30 days from screening) sepsis or clinically significant viral, bacterial, fungal, or parasitic infection, according to the determination of the investigator.\n29. Participants with HIV will be excluded if they have been on ART \\\u003C1 year, have a CD4+ T cell count \\\u003C500 cells\u002Fml (confirmed on repeat), or have two consecutive HIV plasma RNA viral load \\> 48 copies\u002FmL within 1 year of study screening, including requiring the most recent within 3 months of screening. Blips (VL \\> 48 copies\u002FmL but \\\u003C 200 copies\u002FmL) are permitted if preceded and followed by values below the assay limit of quantification.\n30. Immunocompromised as defined by NIH COVID-19 guidelines (see Appendix) and, in the opinion of the investigator, at an unacceptable risk for participating in the study.\n31. Treatment with another investigational drug or device as part of an interventional study within 30 days of study screening.\n32. In the opinion of the investigator, unable to reliably follow-up for the duration of the study and\u002For are unable to follow study restrictions\u002Fprocedures.\n33. Persons of childbearing potential under age 55 who are unwilling or unable to abstain from sex or to use at least one acceptable method of contraception from the time of screening though at least 28 days after the end of the study intervention period. Note: Acceptable methods include barrier contraceptives (condoms or diaphragm) with spermicide, intrauterine devices (IUDs), other contraceptives, oral contraceptive pills, and surgical sterilization. Participants unwilling to be counseled about risks related to pregnancy or breastfeeding.\n34. Currently pregnant or breastfeeding or planning to become pregnant or breastfeed during the course of the study.\n35. Participants actively breastfeeding, who are unwilling to stop breastfeeding for the duration of the trial.\n36. Currently incarcerated\n\nNOTE RE: History of major adverse cardiovascular event (MACE) or traditional risk factors including smoking. For REVERSE-LC, MACE is defined as acute myocardial infarction and stroke. The study team will discuss the risks and benefits of baricitinib and CV events with the participant prior to study entry.\n\nNOTE RE: EBV\u002FCMV Seropositivity - The investigators will not exclude participants based on EBV or CMV seropositivity. The investigators already know that serologic evidence suggesting recent EBV reactivation is associated with Long COVID fatigue and high level EBV responses are associated with neurocognitive Long COVID, but that EBV viremia and IgM is rare. The investigators believe there is equipoise with regard to the potential effects of baricitinib on EBV - it is as likely that inflammation drives EBV reactivation, just as EBV can drive inflammation. For this reason, the investigators think this is best studied as a biological factor correlated with outcomes and that the investigators should not deliberately include or exclude people based on this. CMV seropositivity is associated with improved Long COVID outcomes. Results are not required for screening.",{"count":402,"type":21},550,[172],"The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.",[30,406,407,408],"Sars-CoV-2 Infection","Coronavirus Infections","COVID-19",[408,410,30],"Long COVID Drug Treatment","2026-05-07",{"date":387,"type":38},{"date":414,"type":38},"2024-10-21",{"date":416,"type":21},"2027-07-01",{"name":418,"class":45},"Wes Ely",17,{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":441,"locationsCount":46},"100603296","mitochondrial-function-in-peripheral-blood-mononuclear-cells-muscle-and-skin-of-long-covid-patients-100603296","NCT07134673","Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients","Mitochondrial Oxygen Consumption and Substrate Utilisation In Vitro in Peripheral Blood Mononuclear Cells, and In Vivo on Muscle and Skin in Long COVID Patients and Convalescent Individuals: A Case-Control and Diagnostic Accuracy Study","MitoLoCo","Individuals with long COVID:\n\nInclusion criteria:\n\n* Long COVID diagnosis, based on the WHO definition;\n* Presence of long COVID symptoms for a minimum of 6 months.\n* History of confirmed or documented SARS-CoV-2 infection.\n* Adult (≥18 years of age).\n* Post-COVID-19 Functional Status Scale grade 2-4, while they had a grade 0 before the SARS-CoV-2 infection.\n\nExclusion criteria:\n\n* Pre-existing chronic diseases potentially affecting the functional status scale.\n* Treatment with metabolism altering drugs.\n* \\> 10 standard units of alcohol (10 grams of alcohol\u002Fglass) per week.\n* Unable to understand oral and written instructions in Dutch, French or English.\n* Allergies to medical adhesive bandages.\n* Porphyria and other skin conditions aggravated by sunlight.\n\nConvalescent individuals\n\nInclusion criteria:\n\n* History of confirmed or documented SARS-CoV-2 infection.\n* Complete recovery after the SARS-CoV-2 infection, no history of long COVID based on the WHO definition;\n* Post-COVID-19 Functional Status Scale \\[2\\] grade 0 both before the infection and currently.\n* Adult (≥18 years of age).\n\nExclusion criteria:\n\n* Pre-existing chronic non-communicable diseases (e.g. hypertension, chronic respiratory diseases, diabetes).\n* Treatment with metabolism altering drugs.\n* \\> 10 standard units of alcohol (10 grams of alcohol\u002Fglass) per week.\n* Unable to understand oral and written instructions in Dutch, French or English.\n* Allergies to medical adhesive bandages.\n* Porphyria and other skin conditions aggravated by sunlight.",{"count":429,"type":21},54,"Mitochondria are structures inside cells that are responsible for producing energy from nutrients through a series of steps, using oxygen. To have an idea of how well the mitochondria can produce energy, we can measure how much oxygen they use. The goal of this study is to:\n\n1. To compare the oxygen use between people with long COVID and people who completely recovered after COVID-19, using three techniques that measure the oxygen use in blood cells, on the skin and in the muscle\n2. To test how similar these three techniques are in measuring the oxygen used in the three different tissues\n\nParticipants will:\n\n* Complete surveys,\n* Wear an activity tracker (7 days),\n* Undergo several non-invasive tests, and\n* Donate a blood sample The study will take place in UZ Brussel hospital and will take 2 study visits, approximately 7 days apart.",[30,432],"Post-COVID-19 Condition",[434],"mitochondrial dysfunction","2026-04-21",{"date":437,"type":38},"2026-04-22",{"date":439,"type":38},"2026-01-21",{"date":370,"type":21},{"name":442,"class":45},"Universitair Ziekenhuis Brussel",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":46},"100419054","institut-de-recherche-cliniques-de-montreal-ircm-post-covid-19-ipco-research-clinic-100419054","NCT04736732","Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic","IRCM Post-COVID-19 (IPCO) Research Clinic: a Multidisciplinary Approach to Evaluate Short and Long-term Complications of COVID-19","IPCO","Inclusion Criteria:\n\n* Any gender, ≥ 18 years old\n* Current resident of Quebec\n* Speaks English or French\n* Have a personal email (to which to send reminders and questionnaire by email )\n\nAND\n\n1 of the following criteria:\n\n• Individuals with at least one COVID-19 positive PCR test, serology or antibody\u002Fantigen test in the last 60 months at day of recruitment. In the absence of a positive COVID-19 test, individuals with symptoms consistent with COVID-19 while living with a person who had a confirmed positive PCR, serology or antibody\u002Fantigen COVID-19 test in the last 60 months at day of recruitment (epidemiologic link).\n\nOR\n\n• Individuals who tested negative for COVID-19 while living with a household member who tested positive for COVID-19 or had a close contact with the viral infection in the context of their work, and never had any COVID-19 related symptoms (presumed COVID negative control group).\n\nOR\n\n• Individuals who don't have any COVID-19 related symptoms actually, have never had tested positive, and have had at least one negative PCR, serology or antibody\u002Fantigen COVID-19 test (presumed COVID negative control group).\n\nOR\n\n• Individuals with an undiagnosed viral infection in the last 60 months at day of recruitment and have persistent symptoms (or not) after the participant has recovered from a viral infection.\n\nExclusion Criteria:\n\n* Any participant not deemed appropriate for enrollment according to the PI\n* Known pregnancy (female will not be automatically screened for pregnancy upon enrollment unless there is a possibility that they might be pregnant)","100 Years",{"count":453,"type":21},650,"While many COVID19 studies are focusing on the immediate biological impact of SARS-CoV2 infection, this multidisciplinary research clinic will inform the global community on its recovery phase across patient cohorts with different degrees of disease severity (asymptomatic, mild \\[non-hospitalized\\], moderate\u002Fsevere \\[hospitalized\\]). The primary objectives are to: 1) evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection and 2) establish a post-COVID-19 biobank. The secondary objective is to develop a model that can predict end-organ complications using epidemiological and clinical data. To complete the objectives, the study will follow 6 patient cohorts: Patients who had previous asymptomatic or mild COVID-19 (no need for oxygen), patients who had previous moderate\u002Fsevere COVID-19 (patients who had an oxygen requirement; moderate=oxygen by nasal cannula; severe=oxygen by high flow nasal cannula, non-invasive positive pressure ventilation or intubation), patients who had COVID-19 but did not develop the post-COVID-19 condition, patients who have never had COVID-19, patients who had flu-like symptoms but did not have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset, and patients with flu-like symptoms and have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset. Patients will be recruited into these cohorts using a strategy that targets the following populations: patients that were hospitalized in centers across Montreal, patients already followed at the IRCM (non-COVID-19) clinic, essential workers, and members of the same household as patients already enrolled in the IPCO clinic research protocol. The IPCO clinic research protocol is the first in the province of Quebec to systematically follow patients post-COVID-19 for short- and long-term complications including end-organ damage while building an extensive biobank that can support future mechanistic research projects.",[456,30],"Covid19",[458,459,460,461,462,30],"Post-COVID-19 syndrome","COVID-19-related long-term complications","COVID-19 long haulers","Post-COVID-19 condition","Post-acute sequelae of COVID-19","2026-04-13",{"date":465,"type":38},"2026-04-17",{"date":467,"type":38},"2021-02-01",{"date":469,"type":21},"2027-11-04",{"name":471,"class":45},"Emilia Falcone, MD",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":490,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":46},"100583051","evaluating-the-impact-of-a-functional-and-cognitive-strategy-in-patients-with-long-covid-19-100583051","NCT06871293","Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19","Impact of Functional and Cognitive Rehabilitation, in Adults With Chronic Noncommunicable Diseases and Long Covid-19 , on Their Functional and Cognitive Capacity, Quality of Life, and the Evolution of Their Baseline Condition, in Bogotá D.C.","Inclusion Criteria:\n\n* Covid-19 confirmed.\n* History of arterial hypertension or diabetes mellitus before entering the institutional registries of the FCI-IC or HOMIL, institutional registries of the FCI-IC or HOMIL or before having the diagnosis of SARSCoV-2 infection.\n* Persistence of two or more concurrent symptoms, related to Covid-19 prologue, for at least 4 weeks (persistent, intermittent, or intermittent).\n* At least one of these symptoms must have an impact on activities of daily living. They can be physical (fatigue, dyspnea, myalgias, arthralgias) or neuropsychiatric (cognitive, sleep and emotional alterations).\n* Symptoms unexplained by underlying disease or other condition concomitant with SARS-CoV-2 infection. SARS-CoV-2 infection (determined by prior medical history review and participant interview).\n\nparticipant interview).\n\n\\- Ability to read and attend functional and cognitive rehabilitation sessions or to receive the with evidence-based informational messages.\n\nExclusion Criteria:\n\n* Age \\>80 years.\n* Severely advanced baseline comorbidities prior to SARS-CoV-2 infection.\n* Presence of chronic respiratory disease (partial or permanent supplemental oxygen use), cardiac failure (LVEF\\\u003C40%) or advanced renal disease (GFR\\\u003C30%).\n\nheart failure (LVEF\\\u003C40%) or advanced renal disease (GFR\\\u003C30).\n\n* Two hospitalizations in the year prior to admission to the institutional registries of the FCI-IC and the HOMIL for the patient's underlying disease.\n* Dependence on a caregiver.\n* Orthopedic or cardiopulmonary problems that contraindicate the performance of aerobic exercise.\n* Neuropsychiatric or cognitive limitations that limit understanding or following commands and performing attention exercises.","80 Years",{"count":481,"type":21},374,[59],"This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19.\n\nResearchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients with Long Covid-19.\n\nParticipants will be randomly assigned to one of two groups:\n\n1. Functional and cognitive rehabilitation: Attending weekly in-person sessions for 8 weeks, including supervised physical and cognitive exercises.\n2. Informational support: Receiving weekly evidence-based educational messages for 8 weeks.\n\nParticipants will undergo assessments at baseline, post-intervention, and six months later, including a six-minute walk test, handgrip strength measurement, and questionnaires on disability, anxiety, depression, fatigue, dyspnea, cognitive function, and quality of life.",[485,486,487,488,489,30],"Long COVID-19 Syndrome","COVID 19","Noncommunicable Disease","Hypertension","Diabetes Mellitus",[491,492,493,176,488,489,494,495],"Covid 19","Sars CoV 2","Post-acute Covid-19 syndrome","Noncommunicable disease","Rehabilitation","2026-04-08",{"date":463,"type":38},{"date":499,"type":38},"2025-10-30",{"date":501,"type":21},"2027-01-01",{"name":503,"class":45},"Fundación Cardioinfantil Instituto de Cardiología",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":46},"100523408","long-covid-brain-fog-cognitive-rehabilitation-trial-100523408","NCT06095297","Long COVID Brain Fog: Cognitive Rehabilitation Trial","Technique to Enable Return-to-Work by Employees With Long COVID Brain Fog","Inclusion Criteria:\n\n* \\>3 months post COVID\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* impairment in performance of daily activities\n* reside in community\n* reliable transportation to lab\n* sufficiently mentally and physically fit\n* adequate sight and hearing\n* ability to follow directions, and retain information\n* sufficient English proficiency\n\nExclusion Criteria:\n\n* cognitive impairment due to developmental disability, psychiatric disorder, or substance abuse, TBI or progressive brain disease\n* stroke prior to the onset of COVID\n* current substance abuse disorder\n* prior cognitive processing speed training on DoubleDecision or similar program\n* cannot tolerate trans-auricular vagus nerve stimulation",{"count":88,"type":21},[59],"This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) in-lab training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation (VNS), i.e., trans-auricular VNS (taVNS). Component B will include work-related tasks. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will feature (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, healthy nutrition, and healthy sleep, (C) procedures designed to promote integration of these lifestyle changes into everyday life, and (D) taVNS. This approach is termed Brain Fitness Training (BFT).\n\nA subset of participants, who qualify for and and desire vocational rehabilitation (VR), will receive VR from the Alabama Department of Rehabilitation Services (ADRS) in addition to CICT or BFT. ADRS VR will include career counseling, prescription of on-the-job accommodations, and guidance on return-to-work. Those in the CICT + VR group will also receive on-the-job coaching from a peer mentor for a month after completing training.\n\nCICT, with or without VR, will involve 30 hours of training. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life and improving skills essential to work; the set of the latter procedures is termed the Transfer Package. ta-VNS will administered for 10 minutes before gaming and in-lab target behavior training. To accommodate the demands of participants' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nBFT, with or without VR, will involve 30 hours of training following the same schedule as for CICT. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors (healthy sleep, nutrition and relaxation habits) and the procedures designed to promote transfer of behavior change to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nParticipants will be randomly assigned to the interventions. Randomization will be stratified by whether participants qualify for and desire VR from ADRS or not. If yes, participants will be randomized in equal numbers to CICT + VR or BFT + VR. If no, participants will be randomized in equal numbers to CICT or BFT.\n\nTesting will happen one month before treatment, one day before treatment, one day afterwards, and 6-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life. Another important outcome measure will be whether or not participants were able to return back to work or had significant improvements in their work activities.",[30,253,515,516,201],"Cognitive Impairment","Cognitive Dysfunction",[30,253,515,518,408,519,520],"Vocational Rehabilitation","PASC","Cognitive Rehabilitation","2026-04-06",{"date":463,"type":38},{"date":524,"type":38},"2024-04-25",{"date":526,"type":21},"2027-12",{"name":528,"class":45},"University of Alabama at Birmingham",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":539,"briefSummary":540,"conditions":541,"keywords":544,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":46},"100575018","phase-2-study-to-evaluate-the-efficacy-and-safety-of-plitidepsin-in-adults-with-post-covid-19-condition-pcc-100575018","NCT06766825","Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","Phase II Proof-of-concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","THALASSA","1. Male or female individuals 18 years old or older.\n2. Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test \\[polymerase chain reaction (PCR) or transcription mediated amplification (TMA)\\], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) or positive serology against SARS-CoV-2 N protein regardless vaccination status.\n3. 3 or more symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.\n4. Unable to perform all usual duties\u002Factivities, defined as grades 3 or 4 in PCFS (Annex 3).\n5. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.\n6. Having understood the information provided and capable of providing informed consent\n\nEXCLUSION CRITERIA\n\n1. Last SARS-CoV-2 vaccine dose during the previous 30 days.\n2. Patients with active uncontrolled infections.\n3. Patients infected by SARS-CoV-2 virus in the last 90 days prior to the screening visit.\n4. Patients receiving treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (Annex 1) throughout plitidepsin treatment period and until 24-h washout period.\n5. Pacients receiving chronic glucocorticoid therapy (high-dose corticosteroids \\[ie, 20 mg of prednisone daily or equivalent for ≥2 weeks)\n6. Any of the following cardiac conditions or risk factors:\n\n   * Cardiac infarction or cardiac surgery episode within the last six months 14\n   * History of known congenital QT prolongation;\n   * Known structural cardiomyopathy with abnormal left ventricular ejection fraction (LVEF) \\\u003C50%;\n   * Current clinical evidence of heart failure or acute cardiac ischaemia (New York Heart Association (NYHA) class III-IV).\n7. Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or contraindication to receive systemic glucocorticoids, antihistamine H1\u002FH2 receptor agents, or antiserotonine 5HT3 receptors drugs.\n8. Mast cell activation syndrome.\n9. Females who are pregnant (negative serum or urine pregnancy test required for all females of childbearing potential at screening) or breast-feeding.\n10. Females of childbearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) who are not using highly effective contraceptive methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin. Refer to Annex 2 for contraception requirements.\n11. Unable to consent and\u002For comply with study requirements, in the opinion of the investigator.\n12. Currently participating or participated in a clinical trial within the prior",{"count":538,"type":21},90,[90],"The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with a total of 135 +\u002F-3 days approximately between both periods.\n\nDuring the intervention period, four treatment cycles will be administered, scheduled every 15 days (every 2 weeks), with intravenous (IV) infusion over three consecutive days. After completing the intervention period, a 90-day (+\u002F-5) follow-up period will be conducted.\n\nSubjects in arm A will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31 and Days 43 to 45. Subjects in arm B will receive 1h-IV placebo 1 vial \u002Fday during the first two treatment periods and will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the last two treatment periods. Subjects in arm C will receive 1h-IV placebo 1 vial\u002Fday during the four treatment periods.",[93,362,542,543,30],"Persistent COVID-19","Persistent COVID Condition",[545,408,546,547],"SARS-CoV-2","Long COVID19","Plitidepsin","2026-04-02",{"date":550,"type":38},"2026-04-03",{"date":552,"type":38},"2025-02-07",{"date":554,"type":21},"2026-09-01",{"name":556,"class":45},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":46},"100504979","phase-2-study-of-chemosensory-enhancement-through-neuromodulation-training-scent-for-long-covid-100504979","NCT05855369","Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)","A Randomized Controlled Trial of Smell Training and Trigeminal Nerve Stimulation in the Treatment of COVID-related Persistent Smell Loss","Inclusion Criteria:\n\n* treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia)\n* at least 1-month from SARS-coV-2 PCR-positive and\u002For rapid home-positive tests\n* normal sense of smell prior to COVID\n* naïve to both smell training (ST) and trigeminal nerve stimulation (TNS)\n* able to comprehend English and provide informed consent\n\nExclusion Criteria:\n\n* history of head injury (e.g. sport, accident, combat blast)\n* sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps)\n* neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy)\n* serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder)\n* suicidal ideation within the last month\n* current (≤6 months) heavy cigarette smoker (heavy defined as ≥ 10 pack-years)\n* oral\u002Fnasal steroids or other intranasal medications within the last month\n* immunomodulatory medications\n* pregnant or trying to become pregnant",{"count":565,"type":21},145,[90,172],"Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation. This study requires participants to conduct daily at-home treatment sessions, attend three in-person study visits at the MUSC Department of Psychiatry and Behavioral Sciences, and complete electronic questionnaires over the 12-week trial, and again at the six-month timepoint. Participants in this trial may benefit directly with an improvement in sense of smell. However, participation may also help society more generally, as this study will provide new information about long COVID-related smell loss and its treatment.",[569,570,30],"Smell Dysfunction","Olfactory Disorder",[408,572,573,574,575,576,577,578,579],"Parosmia","Hyposmia","Anosmia","Phantosmia","Dysosmia","Olfactory Training","Neuromodulation","Non-invasive Brain Stimulation",{"date":548,"type":38},{"date":582,"type":38},"2023-10-02",{"date":584,"type":21},"2028-05-31",{"name":586,"class":45},"Medical University of South Carolina",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":608},"100587429","phase-3-long-covid-lc-revitalize---a-long-covid-repurposed-drug-study-100587429","NCT06928272","Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study","LC-REVITALIZE - A Long Covid Repurposed Drug Study","Inclusion Criteria:\n\nEligible participants must meet all the following inclusion criteria:\n\n1. Adults ≥ 18 years of age and ≤ 65 years of age\n2. Previous Covid-19 (SARS-CoV-2 infection) within the past four years, as determined by the site investigator using the following certainty scale (based on available clinical history and\u002For serologic data):\n\n3 - Confirmed Infection (PCR or n-Capsid Test): Prior positive nasopharyngeal or salivary PCR test for Covid-19 (documented proof and\u002For verbal confirmation by participant) or has positive nucleocapsid antibodies results.\n\n2 - Probable Infection (Antigen Test): Participant verbally confirms a prior positive rapid antigen test without PCR confirmation.\n\n1 - Possible Infection (Viral Syndrome and Epidemiological Link): Participant verbally confirms experiencing symptoms consistent with Covid-19 infection and has an epidemiological link (i.e., exposure to a confirmed case) without any positive testing.\n\n3\\. Persistent or new symptoms diagnosed as \"Long Covid\" as defined by the World Health Organization; \"the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection (Covid-19), with these symptoms lasting for at least 2 months with no other explanation\". This diagnosis may come from a healthcare professional experienced in Long Covid diagnosis, or the site investigator. These symptoms must be present for more days than not and must not have been present prior to the onset of SARS-CoV-2 (Covid-19) infection.\n\n4\\. At the time of screening, participants should be experiencing at least one of the following self-reported symptoms or symptom clusters. Participant has self-reported issues with:\n\n1. Fatigue\n2. Breathing\n3. Circulation\n4. Memory, thinking, and\u002For communication\n5. Muscles and\u002For joints\n\n   These five symptoms or symptom clusters were selected based on unpublished data from the National Institutes for Health and Care Research (NIHR, United Kingdom) and their alignment with five validated SBQ scales. The selection was driven by their prevalence and their significant impact on quality of life as reported in symptom assessments.\n\n   5\\. Participant has the ability and is willing to follow study procedures throughout the study\n\n   6\\. Participant can provide informed consent\n\n   Exclusion Criteria:\n\n   Participants who have any one or more of the following criteria at the time of enrollment will be excluded:\n   1. Participants who do not meet the criteria outlined above\n   2. Participants who are unable to provide their informed consent\n   3. Participants who are pregnant, lactating, or plan to become pregnant during the time of the study\n   4. Persons of childbearing potential who are unwilling or unable to abstain from sex or to use at least one acceptable method of contraception from the time of screening through at least 30 days after the end of the study intervention period. Acceptable methods include barrier contraceptives (e.g., condoms or diaphragm) with spermicide, intrauterine devices (IUDs), hormonal contraceptives, oral contraceptive pills, and surgical sterilization. Participants unwilling to be counseled about the risks related to pregnancy or breastfeeding will also be excluded.\n   5. Male participants must take precautions to avoid impregnating a female while participating in this study. If a male participant's partner can become pregnant, she must use an effective and reliable form of birth control, as listed above, during the study and for 30 days after the male participant's last dose of the investigational product. Additionally, male participants must agree to use a latex condom during sexual activity with partners who could become pregnant.\n   6. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n   7. Moderate to severe liver dysfunction, defined as Bilirubin \\> 1.5 x ULN or AST or ALT \\> 2 x ULN\n   8. Hemoglobin (Hbg) \\\u003C 8.0 g\u002FdL\n   9. Absolute neutrophil count (ANC) below 1,000 cells\u002Fmm³, confirmed with repeat testing\n   10. Absolute lymphocyte count (ALC) below 500 cells\u002Fmm³\n   11. Alkaline phosphatase (ALP) levels equal to or greater than three times the upper limit of normal (ULN)\n   12. Creatine phosphokinase (CPK) levels equal to or greater than three times the ULN\n   13. Platelet count below 100,000 cells\u002Fmm³, confirmed with repeat testing\n   14. Platelet count above 500,000 cells\u002Fmm³, confirmed with repeat testing\n   15. Total fasting cholesterol levels of 280 mg\u002FdL or higher, confirmed with repeat testing\n   16. Fasting low-density lipoprotein (LDL) levels of 180 mg\u002FdL or higher, confirmed with repeat testing\n   17. A personal or family history of long QT syndrome or an electrocardiogram (ECG) during screening showing a corrected QT interval (QTc) of 500 milliseconds or greater, calculated using Fridericia's formula\n   18. Participants with HIV diagnosis\n   19. Participants with active hepatitis B or C diagnosis. Note: treated or cleared hepatitis C is not exclusionary.\n   20. Active herpes zoster infection (visible skin lesions) within 3 months prior to screening, or any history of disseminated or complicated herpes zoster or herpes simplex infection (e.g., VZV encephalitis)\n   21. Participants with active or latent tuberculosis\n   22. Immunocompromised status, as determined by the investigator, that places the participant at an unacceptable risk for study participation\n   23. Active malignancy or lymphoproliferative disorder that has not been in remission for at least five years. Localized non-melanoma skin cancers that have been definitively treated are not exclusionary.\n   24. Positive SARS-CoV-2 test in the last 30 days or symptomatic with Covid-19 like illness\n   25. Previous admission to an intensive care unit (ICU) for the treatment of acute COVID-19 infection\n   26. Any history of deep venous thrombosis, pulmonary embolism, unstable angina, atrial fibrillation, ventricular fibrillation, or myocardial infarction or stroke\n   27. History of sepsis or a significant viral, bacterial, fungal, or parasitic infection within 30 days prior to enrollment, as determined by the investigator.\n   28. Use of one or more of the study drugs within 30 days prior to enrollment for the original indication or other purposes\n   29. Known allergic reactions to the components of the study drugs\n   30. Any prior exposure to JAK inhibitors\n   31. Taking any of the listed medications on the prohibited medications list in Appendix A\n   32. Intake or planned consumption of any of the following: Taurine, Curcumin, CoQ10, Creatine, Resveratrol, Fisetin, Nicotinamide mononucleotide (NMN), Nicotinamide adenine dinucleotide (NAD+), Quercetin, Glycine, Spermidine, Arginine alpha-ketoglutarate, Ergothioneine, Alpha Lipoic Acid, Carnitine, Benfotiamine, Carnosine, Crocin, N-acetylcysteine\n   33. Covid vaccinations are prohibited within 30 days prior to enrollment\n   34. Live vaccine within the 30 days before enrollment or plan to receive live vaccines during the study period\n   35. Other vaccines, including influenza vaccine, are prohibited within 14 days of enrollment\n   36. Major surgery within 30 days prior to enrollment or plans for major surgery during the study\n   37. Any other co-existing medical condition or concomitant medication\u002Ftherapy that might in the judgment of the study investigators, potentially impact the participant's safety or ability to adhere to the study protocol or interfere with the meaning of the clinical and research measurements as judged by the study investigators\n   38. Participation in any clinical study within the last 30 days prior to enrollment\n   39. Participants who participated in Phase One of this study (LC-Revitalize) are not eligible to participate in Phase Two\n   40. Currently hospitalized and\u002For incarcerated",{"count":595,"type":21},348,[172],"The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.",[30],[600,252,545],"Post-Covid-19 Condition","2026-03-30",{"date":550,"type":38},{"date":604,"type":38},"2025-09-10",{"date":526,"type":21},{"name":607,"class":45},"Douglas D. Fraser",9,{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":519,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":479,"enrollmentInfo":615,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":133},"100587734","immune-mediated-pathogenic-mechanisms-of-neuro-pasc-in-veterans-100587734","NCT06932237","Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans","Inclusion Criteria:\n\nEligible participants will:\n\n* have a history of SARS-CoV-2 infection 4 weeks prior to enrollment, defined as a positive PCR or home antigen test\n* be able to give informed consent as determined by brief cognitive exam and evaluation of understanding of the risks, benefits, and voluntary nature of the study\n\nAdditionally, participants enrolled as part of the neuro-PASC group must also:\n\n* currently experience neuro-PASC symptoms, not present prior to infection, as confirmed by the \"Long COVID-19 Symptom Assessment\" scale, a self-report measure that consists of 46 common COVID-19 sequela symptoms\n\nExclusion Criteria:\n\nExclusion criteria for all groups:\n\n* diagnosed with dementia, traumatic brain injury, a neurological syndrome (e.g. Parkinson disease, Alzheimer disease), or other progressive cognitive disorder before SARS-CoV-2 infection\n* diagnosed with a mood or psychotic disorder before SARS-CoV-2 infection\n* history of fibromyalgia or chronic fatigue syndrome prior to SARS-CoV-2 infection\n* unstable medical conditions or active uncontrolled autoimmune or inflammatory conditions",{"count":616,"type":21},200,"Mental health symptoms, including cognitive impairment (\"brain fog\"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; and 3) integrate neuropsychiatric and neurological findings with biological data to identify biomarkers and clinical endpoints associated with disease progression or severity, as well as those for promoting brain repair and attenuating those symptoms.",[152,30],[408,203,620,201],"Cognitive","2026-03-25",{"date":623,"type":38},"2026-03-31",{"date":625,"type":38},"2025-02-20",{"date":627,"type":21},"2028-03-31",{"name":211,"class":212},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":451,"enrollmentInfo":636,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":46},"100631271","understanding-the-long-term-impact-of-covid-19-in-adults-100631271","NCT07498504","Understanding the Long-term Impact of COVID-19 in Adults","RECOVER-Adult Cycle 2: A Long-Term Follow Up Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults","Inclusion Criteria:\n\n* RECOVER-Adult 2024 LCRI 11 or greater, as defined by Geng et al, 2024;1 or\n* At least 1 RECOVER-Adult LCRI symptom and either a) poor quality of life (QoL) as defined by a response of \"poor\" on the PROMIS-10 QoL question or b) \"bother scale\" is \"quite a bit\" or \"very much\" for corresponding LCRI symptom; or\n* At least 1 National Academies of Sciences, Engineering, and Medicine (NASEM) common symptom and either a) poor QoL, or b) \"bother scale\" is \"quite a bit\" or \"very much\" for corresponding NASEM symptom.\n\nExclusion Criteria:\n\n* Individuals who have a known or documented hemoglobin lower than 8.5 g\u002FdL,\n* Individuals who have not yet reached the age of majority,\n* Individuals who are unable to provide consent,\n* Individuals who are unwilling to consent to biospecimen collection or are unwilling to participate in the complete protocol, including all assessments and the cycle 2 visit schedule. Note that there are no exclusions related to blood volume collection. For healthy adults, the volume of blood collected (70.9 mL per visit and per year) is substantially lower than the federal minimal risk limit of 550 mL within 8 weeks,\n* Individuals in hospice care,\n* Individuals with a serious medical condition which would prevent in-person participation,\n* Individuals participating in the study NIH RECOVER-Pediatric: Understanding the long-term impact of COVID on children and families, unless enrolled only as caregiver, or\n* Long-term incarcerated individuals",{"count":637,"type":21},5205,"Long COVID (LC) affects an estimated 5-10% of individuals with SARS-CoV-2 causing a persistent physical, cognitive, and functional impairment with potentially severe socioeconomic consequences. While RECOVER-Adult cycle 1 established the largest, most comprehensive U.S. adult LC cohort (14,730 participants), key questions remain about long-term disease trajectories, biological mechanisms, and late-emerging complications. RECOVER-Adult cycle 2 will follow selected participants for two years each, focusing on neurocognitive, cardiopulmonary and infection-associated chronic conditions (IACC) such as Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) and autonomic dysfunction. Using a case-cohort design, the study will investigate disease persistence versus resolution, biological mechanisms, and onset of new chronic illnesses, generating critical insights to guide prevention, treatment, and public health policy.",[30,640],"Long Covid19","2026-03-23",{"date":643,"type":38},"2026-03-27",{"date":645,"type":21},"2026-05",{"date":647,"type":21},"2030-04",{"name":649,"class":45},"NYU Langone Health"]